BioSpace News Archive

IN8bio, Inc. today announced William Ho, CEO and co-founder, will participate in a fireside chat at the H.C. Wainwright Immune Cell Engager Virtual Conference on Thursday, August 17, 2023 at 2:00 pm ET.

Akari Therapeutics, Plc today announced that Akari will change the ratio of its American Depositary Shares (ADSs) to ordinary shares from one ADS representing one hundred ordinary shares to a new ratio of one ADS representing two thousand ordinary shares.

OnCusp Therapeutics announced today the clearance of its Investigational New Drug (IND) Application for CUSP06 by the U.S. Food and Drug Administration (FDA).

Research has shown that a novel antibody generated to target an ‘essential amino acid sequence’ of both interleukin-17A and F has greater activity and potentially fewer side effects than existing biological therapies for conditions such as as rheumatoid arthritis (RA), psoriasis, and inflammatory bowel disease (IBD).

Alltrna, a Flagship Pioneering company unlocking transfer RNA biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, announced that it has appointed Chris Henderson, Ph.D., as Chief Scientific Officer and promoted William Kiesman, Ph.D., to Chief Technology Officer.

RegeneRx Biopharmaceuticals, Inc. announced that it has today effected a 1-for-100 reverse split in the outstanding shares of Common Stock of the Company and has filed the requisite Form 15 to suspend and terminate the Company’s continued obligations to file reports with the SEC pursuant to Sections 13(d) and 15(d) of the Securities Exchange Act of 1934, as amended.

Calliditas Therapeutics AB announced publication in The Lancet of the full data from the Phase 3 NefIgArd Study with Nefecon® delayed release capsules/Kinpeygo®) in adults with Primary IgA nephropathy.

The EGM resolved to authorise the Board of Directors to, during the period up to the Annual General Meeting 2024, resolve on issue of new common shares with preferential rights for the company’s shareholders.

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced its unaudited financial results for the six months ended June 30, 2023.

AIM ImmunoTech Inc. reported its financial results for the second quarter 2023 and provided a business update.